Rodger E Tiedemann

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo
    Rodger E Tiedemann
    Division of Hematology and Oncology, Comprehensive Cancer Center, Mayo Clinic, Scottsdale, AZ 85259, USA
    Blood 113:4027-37. 2009
  2. ncbi Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6
    Rodger E Tiedemann
    Division of Hematology Oncology, Mayo Clinic Arizona, 13400 Shea Blvd, Scottsdale, AZ 85259, USA
    Blood 115:1594-604. 2010
  3. ncbi Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity
    Rodger E Tiedemann
    Mayo Clinic, Comprehensive Cancer Center, Division of Hematology and Oncology, Scottsdale, Arizona, USA
    J Clin Invest 118:1750-64. 2008

Detail Information

Publications3

  1. ncbi Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo
    Rodger E Tiedemann
    Division of Hematology and Oncology, Comprehensive Cancer Center, Mayo Clinic, Scottsdale, AZ 85259, USA
    Blood 113:4027-37. 2009
    ....
  2. ncbi Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6
    Rodger E Tiedemann
    Division of Hematology Oncology, Mayo Clinic Arizona, 13400 Shea Blvd, Scottsdale, AZ 85259, USA
    Blood 115:1594-604. 2010
    ..As mice that lack GRK6 are healthy, inhibition of GRK6 represents a uniquely targeted novel therapeutic strategy in human multiple myeloma...
  3. ncbi Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity
    Rodger E Tiedemann
    Mayo Clinic, Comprehensive Cancer Center, Division of Hematology and Oncology, Scottsdale, Arizona, USA
    J Clin Invest 118:1750-64. 2008
    ..These data support targeted repression of cyclin D genes as a therapeutic strategy for human malignancies...